Clinical Trial Update: Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

The Phase 2 study of CX-3543 in relapsed or refractory B-cell chronic lymphocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CX-3543 (CX-3543)

Snippet

Sponsor: Cylene Pharmaceuticals | Conditions: B-Cell Chronic Lymphocytic Leukemia | Phase 2 | Status: WITHDRAWN